Cargando…
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824374/ https://www.ncbi.nlm.nih.gov/pubmed/33396548 http://dx.doi.org/10.3390/toxins13010022 |
_version_ | 1783640061684744192 |
---|---|
author | Samadzadeh, Sara Brauns, Raphaela Hefter, Harald |
author_facet | Samadzadeh, Sara Brauns, Raphaela Hefter, Harald |
author_sort | Samadzadeh, Sara |
collection | PubMed |
description | Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clinical data and course of treatment of five long-term treated patients with cervical dystonia out of therapy response norms are presented: a patient who was supersensitive to standard dose and has required dose adjustment to lower dose of BoNT; one patient who worsened under a standard dose, but responded excellently to twice the standard dose; one insensitive patient who responded poorly for years to a dose well above the standard dose, but responded when dose was further increased; and two patients with a totally different response pattern to BoNT/A preparation 1, but the development of a neutralizing antibody induced secondary treatment failure in both cases and a totally different response after switch to BoNT/A preparation 2. Conclusions: These five patients indicate that the response of a patient to a BoNT preparation may be unexpected. Therefore, cautious onset of BoNT therapy is recommended as well as consequent dose adjustment later on and even switch to another BoNT/A preparation when a patient has already developed NABs against BoNT/A. |
format | Online Article Text |
id | pubmed-7824374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78243742021-01-24 The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia Samadzadeh, Sara Brauns, Raphaela Hefter, Harald Toxins (Basel) Communication Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clinical data and course of treatment of five long-term treated patients with cervical dystonia out of therapy response norms are presented: a patient who was supersensitive to standard dose and has required dose adjustment to lower dose of BoNT; one patient who worsened under a standard dose, but responded excellently to twice the standard dose; one insensitive patient who responded poorly for years to a dose well above the standard dose, but responded when dose was further increased; and two patients with a totally different response pattern to BoNT/A preparation 1, but the development of a neutralizing antibody induced secondary treatment failure in both cases and a totally different response after switch to BoNT/A preparation 2. Conclusions: These five patients indicate that the response of a patient to a BoNT preparation may be unexpected. Therefore, cautious onset of BoNT therapy is recommended as well as consequent dose adjustment later on and even switch to another BoNT/A preparation when a patient has already developed NABs against BoNT/A. MDPI 2020-12-31 /pmc/articles/PMC7824374/ /pubmed/33396548 http://dx.doi.org/10.3390/toxins13010022 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Samadzadeh, Sara Brauns, Raphaela Hefter, Harald The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title | The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title_full | The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title_fullStr | The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title_full_unstemmed | The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title_short | The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia |
title_sort | extreme ends of the treatment response spectrum to botulinum toxin in cervical dystonia |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824374/ https://www.ncbi.nlm.nih.gov/pubmed/33396548 http://dx.doi.org/10.3390/toxins13010022 |
work_keys_str_mv | AT samadzadehsara theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia AT braunsraphaela theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia AT hefterharald theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia AT samadzadehsara extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia AT braunsraphaela extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia AT hefterharald extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia |